
Céline M Laumont

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6734439/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Noncoding regions are the main source of targetable tumor-specific antigens. Science Translational Medicine, 2018, 10, .	5.8	374
2	Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames. Nature Communications, 2016, 7, 10238.	5.8	210
3	Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides. Nature Communications, 2014, 5, 3600.	5.8	111
4	Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nature Reviews Cancer, 2022, 22, 414-430.	12.8	109
5	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunological Reviews, 2017, 280, 165-174.	2.8	82
6	The nature of self for T cells—a systems-level perspective. Current Opinion in Immunology, 2015, 34, 1-8.	2.4	61
7	Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-l-associated epitopes. Immunity, 2021, 54, 737-752.e10.	6.6	58
8	Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy. Cellular and Molecular Life Sciences, 2018, 75, 607-621.	2.4	53
9	Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer. Cancer Immunology Research, 2020, 8, 544-555.	1.6	48
10	Rejection of Leukemic Cells Requires Antigen-Specific TÂCells with High Functional Avidity. Biology of Blood and Marrow Transplantation, 2014, 20, 37-45.	2.0	10
11	Meeting report – 9th IRIC International Symposium on Molecular Targets in Cancer Genomics. Journal of Cell Science. 2015. 128. 3521-3524.	1.2	0